INTERVIEWS

Vanity Fair Jul 13, 2024

Ketamine’s Long, Strange Trip: The Cred of This Miracle Med Has Gotten Murkier and, Somehow, More Promising

An assessment of K by a science writer who has used the drug to combat depression and long-haul COVID.

Lucid News Jul 11, 2024

Real-World Challenges of Psychedelic Therapies

The potential benefits of psychedelic-assisted therapies are intertwined with real-world concerns about their safety and efficacy.

Vicente LLP Jul 8, 2024

Training Program Applications Now Open for Colorado’s Natural Medicine Program

With the Approved Facilitator Training Programs (AFTP) rules in effect as of June 30, The Office of Natural Medicine Licensure has opened applications for AFTP. These are the first applications available under Colorado’s new Natural Medicine Health program.

Marijuana Moment Jul 8, 2024

Olympia, Wash., Weighs Psychedelics Decriminalization Proposal

Local leaders in Olympia, Washington, are considering a resolution that would direct law enforcement to make the prohibition of psilocybin and other psychedelic substances a low enforcement priority, with a public hearing on the proposal expected in coming weeks.

Scientific American Jul 3, 2024

Is a Drug Even Needed to Induce a Psychedelic Experience?

A Stanford anesthesiologist deconstructs the component parts of what it means to undergo a psychedelic trip.

Bloomberg Jul 3, 2024

Oregon Is Teaching the States How to Tax Psychedelic Mushrooms

While psilocybin remains a Schedule I drug under the Federal Controlled Substances Act, at least a dozen other states are monitoring Oregon and drafting their own plans to decriminalize psychedelic substances.

PsyPost Jul 2, 2024

Surge in Microdosing Interest Linked to Loosened Drug Regulations, Study Finds

A new study published in JAMA Health Forum has highlighted this surge, noting a 1250% rise in microdosing-related Google searches from 2015 to 2023, with over three million searches in 2023 alone.

MSN Jul 1, 2024

Psychedelic Candy Recall: FDA Probe on as Mushroom Edibles Sicken Consumers

Diamond Shruumz products are now linked to illnesses in 20 states. The FDA and Centers for Disease Control (CDC) are working in partnership with the USA’s poison centers, and state and local partners.

Psychedelic Alpha June 28, 2024

ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted Therapy; Lykos Responds

There’s no substantive change from its draft evidence report’s determination, or from the vote of its independent panel which resoundingly rejected the intervention.

ScienceBlog June 27, 2024

Mushrooms Outpace MDMA as America’s Favorite Psychedelic, Study Reveals

The study, based on a national survey, found that about 12% of respondents reported using psilocybin at some point in their lives, with 3.1% using it in the past year. This translates to an estimated 8 million American adults who used psilocybin in 2023 alone.

Benzinga June 26, 2024

Fluence, Enthea Partner to Expand Reimbursement and Training in Ketamine-Assisted Therapy

Psychedelic therapy training company Fluence partnered with psychedelic healthcare insurance plans provider Enthea to expand reimbursement for services from Fluence-trained clinicians offering ketamine-assisted therapy.

KQED June 26, 2024

California Drops Psychedelic Therapy Legalization Bill, Again

A bipartisan bill that would have allowed three counties to operate facilities for three years where veterans and former first responders could use psilocybin under the supervision of a licensed physician died in committee on Tuesday.

Westword June 25, 2024

CU Denver Launches Psychedelic Research Center in Downtown Denver

Studies will focus on mental and physical health applications as well as the societal and economic impact of Colorado’s Magic Mushrooms Law.

Scientific American June 24, 2024

Should Next-Generation Psychedelics Skip the Trip?

Although some researchers argue that a psychedelic experience is essential for a long-term improvement in mental health, nobody knows for sure whether it will be possible to retain therapeutic benefit while avoiding the trip.

Arizona Daily Star June 19, 2024

Arizona Gov. Vetoes Bill to Legalize Psychedelic Therapy

Gov. Katie Hobbs (D) said, “Arizonans with depression and PTSD deserve access to treatments that may be seen as outside the mainstream. But they should not be the subject of experiments for unproven therapies with a lack of appropriate guardrails.”

PsyPost June 18, 2024

Older Adults Who Have Used Psychedelics Tend to Have Better Executive Functioning

Older individuals who have used psychedelics tend to exhibit better cognitive functioning and fewer depressive symptoms compared to those who have not, according to new research.

Marijuana Moment June 16, 2024

Arizona Bill to Legalize Psilocybin Service Centers Heads to Governor’s Desk

If enacted into law, the Department of Human Services (DHS) would be authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could administer the psychedelic.

Psychedelic Alpha June 14, 2024

Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals

Over the past few years, sources at the company have repeatedly told Psychedelic Alpha that it had not filed any patents, to their knowledge, meaning it’s unclear the extent to which portions of its staff were left in the dark regarding its IP strategy.

Marijuana Moment June 12, 2024

Bipartisan Calif. Senators File Bill to Create Psilocybin Pilot Program for Veterans and First Responders

The move comes weeks after a Senate committee effectively killed a broader bill that would have legalized psychedelic service centers where adults 21 and older could have accessed psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.

New York Times June 11, 2024

FDA Warns Against ‘Microdosing’ Mushroom Chocolate Bars Linked to Severe Illnesses

At least eight people have fallen ill after eating Diamond Shruumz products, including several who had seizures or needed to be put on ventilators.

Search